Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials
Abstract In Japan, the choice of anti-diabetic medication is officially recommended according to the patient’s glycemic condition and disease phenotype, unlike most other regions where metformin is recommended as the first-line medication. There has been an increase in the number of available glucos...
Main Authors: | Atsushi Tanaka, Koichi Node |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-02-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12933-019-0834-0 |
Similar Items
-
Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors
by: Atsushi Tanaka, et al.
Published: (2021-02-01) -
A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors
by: Maneesha Khalse, et al.
Published: (2018-01-01) -
Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus
by: Geert Jan Biessels, et al.
Published: (2018-01-01) -
The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
by: Shin S, et al.
Published: (2016-03-01) -
Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
by: Fang Zhang, et al.
Published: (2020-06-01)